Trial Profile
An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms AMBER II
- Sponsors GlaxoSmithKline; GSK
- 27 Apr 2017 Status changed from completed to discontinued.
- 18 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2015 Planned End Date changed from 1 Feb 2019 to 1 Sep 2015 as reported by ClinicalTrials.gov.